Kairos Pharma, LTD. Logo

Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):
US48301N1046
LEI:
Country:
United States of America
Address:
2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY
PSYENCE BIOMEDICAL LTD. Logo
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM
PTC THERAPEUTICS, INC. Logo
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America
PTCT
Pulmatrix, Inc. Logo
Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.
United States of America
PULM
PUMA BIOTECHNOLOGY, INC. Logo
Develops and commercializes innovative cancer therapeutics, with an approved drug and a clinical pipeline.
United States of America
PBYI
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland
PUR
PureTech Health plc Logo
A clinical-stage biotherapeutics firm developing new medicines for devastating diseases.
United States of America
PRTC

Talk to a Data Expert

Have a question? We'll get back to you promptly.